Robust clinical trial data are proving to be fundamental in shaping investor confidence and driving strategic decisions in the biotechnology sector. Between 2015 and 2020 alone, biotech investments have heavily favored companies with advanced clinical-stage candidates, underscoring the close link between science and capital.
Evaluating a biotech company’s clinical pipeline and trial maturity is often more insightful than financials alone. At Axcellant, we see this impact firsthand: from designing robust Phase II studies to supporting pivotal Phase III trials, we’re helping biotech innovators translate scientific promise into commercial value.
Curious about how clinical strategy can align with business success? Let’s continue the conversation.
Read the full article (in Polish) here.
Clinical trials are often seen as a regulatory necessity, but for biotech and medtech startups, they can be much more.…
Axcellant participated in SNMMI’s 2025 Annual Meeting in New Orleans, where nearly 8,000 professionals in nuclear medicine and molecular imaging gathered…
Axcellant participated in the PET Symposium 2025, held in Turku, marking 50 years of PET radiochemistry at the Turku PET…
Copyright @ 2025 Axcellant